Back to top
more

United Therapeutics (UTHR)

(Delayed Data from NSDQ)

$236.93 USD

236.93
476,358

+1.62 (0.69%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $237.01 +0.08 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for UTHR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

United Therapeutics Corporation [UTHR]

Reports for Purchase

Showing records 441 - 460 ( 583 total )

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 441

07/02/2014

Industry Report

Pages: 48

July and 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 442

06/27/2014

Daily Note

Pages: 5

Additional Share Buyback Rewards Long- Term Stock Holders; Reiterate OUTPERFORM and $119 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 443

06/27/2014

Industry Report

Pages: 6

LIFE SCIENCES AND HEALTH CARE - The Week Ahead in Life Sciences - Upcoming Events for the Week of June 30

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 444

06/27/2014

Daily Note

Pages: 5

Additional Share Buyback Rewards Long-Term Stock Holders; Reiterate OUTPERFORM and $119 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 445

06/09/2014

Industry Report

Pages: 5

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 446

05/27/2014

Company Report

Pages: 8

Price: 24.95

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 447

05/21/2014

Industry Report

Pages: 47

Emerging Pharmaceuticals - May and 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 448

05/19/2014

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of May 19

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 449

05/06/2014

Daily Note

Pages: 5

Announces Deal to Develop Humanized Pig Organs for Clinical Transplantation

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 450

05/06/2014

Daily Note

Pages: 5

Announces Deal to Develop Humanized Pig Organs for Clinical Transplantation. Reiterate OUTPERFORM & $119 PT.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 451

05/01/2014

Company Report

Pages: 8

Price: 24.95

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 452

04/29/2014

Company Report

Pages: 9

Q1 Financials: Despite Transiently Choppy Tyvaso and Adcirca, Growth Remains Intact In Our View; Reiterate OUTPERFORM and $119 PT.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 453

04/22/2014

Company Report

Pages: 10

Q1 Preview: We Anticipate Sales Growth Continued into Q1. Reiterate OUTPERFORM and $119 PT.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 454

04/09/2014

Daily Note

Pages: 46

April and 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 455

04/04/2014

Company Report

Pages: 8

Price: 24.95

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 456

04/01/2014

Company Report

Pages: 14

Corporate Update: With Multiple Product Launches, We See Growth Continuing For The Foreseeable Future.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 457

02/23/2014

Industry Report

Pages: 6

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 458

02/23/2014

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 24

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 459

02/04/2014

Daily Note

Pages: 52

February and 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 460

02/04/2014

Daily Note

Pages: 52

February and 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party